Jump to:

Zebinix: new for epilepsy

29 October 2009, 9:26am

Zebinix (eslicarbazepine acetate) has been launched as an adjunctive treatment for partial-onset seizures with or without secondary generalisation.

Zebinix: new for epilepsy

Eslicarbazepine acetate is a carboxamide derivative.

The drug's exact mechanism of action is unknown, but it is suggested that it works by stabilising the inactivated state of voltage-gated sodium channels, preventing their return to the activated state therefore sustaining repetitive neuronal firing.

Zebinix must be added to existing anticonvulsant therapy and the dose increased gradually. Zebinix is licensed for the management of epilepsy in adults; caution should be exercised when managing elderly patients and it is not recommended for use in children.

View Zebinix drug record

Further information: Eisai


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

You must log in to make full use of all the site content and features.

New users can register here free for full site access.

 

MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

NICE Guidance: IBS

NICE Guidance: IBS

MIMS Summary of
NICE guideline

NICE Guidance: Lipid Modification

NICE Guidance: Lipid Modification

MIMS Summary of
NICE guideline

Quick-reference table: antibiotics

Quick-reference table: antibiotics

Treatment regimens for common infections

Referral Guidelines for Breast Disorders

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines

Back to top